NASDAQ:OPHT - Ophthotech Stock Price, Price Target & More

$2.60 -0.03 (-1.14 %)

(As of 04/23/2018 04:00 PM ET)

Previous Close$2.63

Today's Range$2.58 - $2.67

52-Week Range$2.24 - $3.60

Volume120,174 shs

Average Volume285,032 shs

Market Capitalization$95.18 million

P/E Ratio0.83

Dividend YieldN/A

Beta1.36

About Ophthotech (NASDAQ:OPHT)

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach and other gene delivery technologies to target retinal diseases. The company was founded in 2007 and is headquartered in New York, New York.

Receive OPHT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:OPHT

CUSIPN/A

Webwww.ophthotech.com

Phone212-845-8200

Debt

Debt-to-Equity RatioN/A

Current Ratio13.69%

Quick Ratio13.69%

Price-To-Earnings

Trailing P/E Ratio0.83

Forward P/E Ratio-1.52

P/E GrowthN/A

Sales & Book Value

Annual Sales$209.98 million

Price / Sales0.45

Cash Flow$3.2099 per share

Price / Cash0.81

Book Value$1.06 per share

Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)$3.17

Net Income$114.20 million

Net Margins26.69%

Return on Equity-230.07%

Return on Assets57.20%

Miscellaneous

Employees38

Outstanding Shares36,190,000

How to Become a New Pot Stock Millionaire

Ophthotech (NASDAQ:OPHT) Frequently Asked Questions

What is Ophthotech's stock symbol?

Ophthotech trades on the NASDAQ under the ticker symbol "OPHT."

How were Ophthotech's earnings last quarter?

Ophthotech (NASDAQ:OPHT) announced its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.58) by $0.32. Ophthotech had a net margin of 26.69% and a negative return on equity of 230.07%. During the same period last year, the company earned ($1.86) EPS. View Ophthotech's Earnings History.

When is Ophthotech's next earnings date?

Ophthotech is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Ophthotech.

What price target have analysts set for OPHT?

2 Wall Street analysts have issued 12 month price targets for Ophthotech's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Ophthotech's share price to reach $4.00 in the next year. View Analyst Ratings for Ophthotech.

Who are some of Ophthotech's key competitors?

Some companies that are related to Ophthotech include Scpharmaceuticals (SCPH), Teligent (TLGT), Protagonist Therapeutics (PTGX), Zafgen (ZFGN), Evolus (EOLS), Spero Therapeutics (SPRO), Spring Bank Pharmaceuticals (SBPH), Avid Bioservices (CDMO), Kamada (KMDA), Proteostasis Therapeutics (PTI), Intec Pharma (NTEC), XBiotech (XBIT), Immune Design (IMDZ), NewLink Genetics (NLNK), Tetraphase Pharmaceuticals (TTPH), Newron Pharmaceuticals (NWPHF), BioXcel Therapeutics (BTAI) and Zynerba Pharmaceuticals (ZYNE).

Who are Ophthotech's key executives?

Ophthotech's management team includes the folowing people:

Dr. David R. Guyer, Chairman and Chief Exec. Officer (Age 58)
Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 62)
Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 57)
Mr. David F. Carroll M.B.A., CFO & Treasurer (Age 52)
Mr. Keith Westby M.B.A., Chief Operating Officer and Sr. VP (Age 43)

Has Ophthotech been receiving favorable news coverage?

Press coverage about OPHT stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.17 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.92 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Ophthotech?

Shares of OPHT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ophthotech's stock price today?

One share of OPHT stock can currently be purchased for approximately $2.60.

How big of a company is Ophthotech?

Ophthotech has a market capitalization of $95.18 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $114.20 million in net income (profit) each year or $3.17 on an earnings per share basis. Ophthotech employs 38 workers across the globe.

How can I contact Ophthotech?

Ophthotech's mailing address is ONE PENN PLAZA 19TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at 212-845-8200 or via email at [email protected]

MarketBeat Community Rating for Ophthotech (OPHT)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		245 (Vote Outperform)
Underperform Votes:		191 (Vote Underperform)
Total Votes:		436

MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe OPHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Ophthotech (NASDAQ:OPHT) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Ophthotech in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 53.85%. The high price target for OPHT is $4.00 and the low price target for OPHT is $4.00. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	1.50	1.50	2.00	2.00
Ratings Breakdown:	1 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 12 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$4.00	$4.00	$4.00	$47.3333
Price Target Upside:	53.85% upside	31.15% upside	43.37% upside	1,596.54% upside

Ophthotech (NASDAQ:OPHT) Consensus Price Target History

Price Target History for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ:OPHT) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/19/2018	JPMorgan Chase	Downgrade	Neutral -> Underweight		Low
9/21/2017	Stifel Nicolaus	Reiterated Rating	Hold	$4.00	Low
12/13/2016	Gabelli	Downgrade	Buy -> Hold		N/A
12/13/2016	Morgan Stanley	Downgrade	Overweight -> Equal Weight		N/A
12/12/2016	Goldman Sachs	Upgrade	Sell -> Neutral		N/A
12/12/2016	Leerink Swann	Downgrade	Outperform -> Market Perform		N/A
12/12/2016	BTIG Research	Downgrade	Buy -> Neutral		N/A
12/12/2016	Cowen	Downgrade	Outperform -> Market Perform		N/A
12/12/2016	Citigroup	Downgrade	Buy -> Neutral		N/A
12/12/2016	Barclays	Downgrade	Overweight -> Equal Weight		N/A
12/12/2016	SunTrust Banks	Downgrade	Buy -> Hold		N/A
12/12/2016	Chardan Capital	Downgrade	Buy -> Neutral	$15.00	N/A

(Data available from 4/23/2016 forward)

Ophthotech (NASDAQ:OPHT) Earnings History and Estimates Chart

Earnings by Quarter for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ:OPHT) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.71 EPS
Next Year EPS Consensus Estimate: $-1.31 EPS

Ophthotech (NASDAQ OPHT) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018
2/27/2018	Q4 2017	($0.58)	($0.26)	$1.00 million		View	Listen
11/8/2017	Q3 2017	$4.38	$5.25	$185.00 million	$206.65 million	View	N/A
7/26/2017	Q2 2017	($1.07)	($0.62)	$1.38 million	$1.66 million	View	N/A
5/3/2017	Q1 2017	($1.31)	($1.20)	$1.94 million	$1.66 million	View	Listen
2/28/2017	Q4 2016	($1.64)	($1.86)	$6.27 million	$5.32 million	View	N/A
11/8/2016	Q316	($1.64)	($1.71)	$6.20 million	$1.67 million	View	Listen
8/3/2016	Q216	($1.05)	($0.85)	$18.64 million	$28.20 million	View	Listen
5/4/2016	Q116	($1.33)	($1.03)	$7.22 million	$15.70 million	View	Listen
2/24/2016	Q415	($1.35)	($1.02)	$7.59 million	$4.78 million	View	Listen
11/5/2015	Q315	($0.98)	($1.14)	$11.31 million	$3.40 million	View	N/A
8/5/2015	Q215	($1.02)	($1.08)	$2.77 million	$1.60 million	View	N/A
5/11/2015	Q115	($0.75)	$0.22	$3.68 million	$41.70 million	View	Listen
2/23/2015	Q414	($0.57)	($1.06)	$12.36 million	$1.68 million	View	N/A
11/11/2014	Q314	($0.62)	$0.31	$8.02 million	$39.58 million	View	N/A
8/6/2014	Q214	($0.56)	($1.57)	$4.31 million		View	N/A
5/13/2014	Q1	($0.67)	($0.64)			View	Listen
2/27/2014		($0.50)	($0.65)			View	N/A
11/13/2013	Q313	($1.00)	($10.26)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Ophthotech (NASDAQ:OPHT) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Ophthotech (NASDAQ OPHT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 61.81%

Insider Trading History for Ophthotech (NASDAQ:OPHT)

Institutional Ownership by Quarter for Ophthotech (NASDAQ:OPHT)

Ophthotech (NASDAQ OPHT) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/2/2018	Glenn Sblendorio	Insider	Sell	6,838	$2.69	$18,394.22	55,245
1/5/2018	Barbara A Wood	SVP	Sell	602	$3.17	$1,908.34	17,064
1/5/2018	David R Guyer	Insider	Sell	3,798	$3.17	$12,039.66	42,458
1/5/2018	Keith Westby	COO	Sell	317	$3.17	$1,004.89	25,300
1/3/2018	Keith Westby	COO	Sell	356	$3.24	$1,153.44	24,956
1/2/2018	Barbara A Wood	SVP	Sell	5,289	$3.19	$16,871.91	20,472
1/2/2018	David R Guyer	Insider	Sell	16,520	$3.19	$52,698.80	50,494
1/2/2018	Glenn Sblendorio	CEO	Sell	8,089	$3.19	$25,803.91	44,584
7/5/2017	Barbara A Wood	SVP	Sell	5,119	$2.58	$13,207.02	13,451
7/5/2017	David Francis Carroll	CFO	Sell	3,284	$2.58	$8,472.72	7,500
7/5/2017	David R Guyer	Chairman	Sell	17,678	$2.58	$45,609.24	37,692
7/5/2017	Glenn Sblendorio	CEO	Sell	7,828	$2.58	$20,196.24	31,992
6/13/2017	David E Redlick	Director	Sell	700	$2.52	$1,764.00	1,050
4/3/2017	Glenn Sblendorio	CFO	Sell	7,388	$3.56	$26,301.28
1/5/2017	David R Guyer	CEO	Sell	3,785	$4.96	$18,773.60	10,997
1/5/2017	Henric Bjorn Bjarke	SVP	Sell	316	$4.96	$1,567.36	1,700
1/5/2017	Samir Chandrakant Patel	President	Sell	3,844	$4.96	$19,066.24	18,332
1/3/2017	Barbara A Wood	SVP	Sell	675	$4.90	$3,307.50	1,375
1/3/2017	David R Guyer	CEO	Sell	3,484	$4.90	$17,071.60	8,231
1/3/2017	Samir Chandrakant Patel	President	Sell	2,999	$4.90	$14,695.10	16,406
12/23/2016	Barbara A. Wood	SVP	Sell	746	$4.92	$3,670.32
12/22/2016	Glenn Sblendorio	CFO	Sell	1,079	$4.85	$5,233.15
12/15/2016	A/S Novo	Major Shareholder	Sell	3,610,487	$4.87	$17,583,071.69	1,405,487
11/1/2016	David R Guyer	CEO	Sell	22,060	$35.61	$785,556.60	24,541
10/3/2016	David R Guyer	CEO	Sell	22,060	$44.37	$978,802.20	24,541
9/29/2016	Samir Chandrakant Patel	President	Sell	20,000	$55.17	$1,103,400.00	24,239
8/29/2016	Samir Chandrakant Patel	President	Sell	20,000	$52.80	$1,056,000.00
8/1/2016	David R Guyer	CEO	Sell	24,060	$64.47	$1,551,148.20	56,451
7/29/2016	Samir Chandrakant Patel	President	Sell	20,000	$64.21	$1,284,200.00	176,031
7/1/2016	David R Guyer	CEO	Sell	24,060	$52.12	$1,254,007.20	56,451
6/30/2016	Samir Chandrakant Patel	President	Sell	41,846	$51.23	$2,143,770.58	174,992
6/3/2016	Axel Bolte	Director	Buy	3,500	$56.97	$199,395.00	6,000
6/2/2016	Glenn Sblendorio	CFO	Sell	671	$57.20	$38,381.20	1,750
6/1/2016	David R Guyer	CEO	Sell	30,060	$52.71	$1,584,462.60	62,451
5/31/2016	Samir Chandrakant Patel	President	Sell	20,000	$53.32	$1,066,400.00	213,377
5/24/2016	A/S Novo	Major Shareholder	Sell	1,300,000	$49.00	$63,700,000.00	3,610,489
5/2/2016	David R Guyer	CEO	Sell	22,060	$46.18	$1,018,730.80	54,451
4/29/2016	Samir Chandrakant Patel	President	Sell	20,000	$46.79	$935,800.00	231,008
4/1/2016	David R Guyer	CEO	Sell	22,060	$44.11	$973,066.60	54,451
3/29/2016	Samir Chandrakant Patel	President	Sell	20,000	$41.85	$837,000.00	248,410
3/1/2016	David R Guyer	CEO	Sell	22,060	$45.48	$1,003,288.80	54,451
2/29/2016	Samir Chandrakant Patel	President	Sell	20,000	$45.13	$902,600.00	263,736
1/29/2016	Samir Chandrakant Patel	President	Sell	20,000	$53.59	$1,071,800.00	260,911
1/28/2016	David R. Guyer	CEO	Sell	18,598	$53.63	$997,410.74	32,391
1/11/2016	Nicholas Galakatos	Director	Sell	3,000	$65.72	$197,160.00	5,684
1/4/2016	Barbara A. Wood	SVP	Sell	1,000	$76.37	$76,370.00	746
12/30/2015	David R. Guyer	CEO	Sell	18,582	$78.82	$1,464,633.24	29,910
12/30/2015	Glenn Sblendorio	Director	Sell	2,000	$80.00	$160,000.00
12/29/2015	Samir Chandrakant Patel	President	Sell	1,184	$77.50	$91,760.00	278,605
12/24/2015	Samir Chandrakant Patel	President	Sell	26,036	$77.09	$2,007,115.24	278,605
12/10/2015	Nicholas Galakatos	Director	Sell	3,000	$64.44	$193,320.00	7,684
12/1/2015	Barbara A. Wood	SVP	Sell	2,000	$63.24	$126,480.00
11/30/2015	David R. Guyer	CEO	Sell	18,582	$62.49	$1,161,189.18	29,910
11/24/2015	Samir Chandrakant Patel	President	Sell	27,215	$60.27	$1,640,248.05	278,605
11/18/2015	Nicholas Galakatos	Director	Sell	1,500	$60.00	$90,000.00	9,684
11/5/2015	Samir Chandrakant Patel	President	Sell	20,687	$53.55	$1,107,788.85	278,605
10/21/2015	Samir Chandrakant Patel	President	Sell	27,215	$43.27	$1,177,593.05	259,292
10/16/2015	Barbara A. Wood	SVP	Sell	2,000	$45.00	$90,000.00
9/29/2015	David R. Guyer	CEO	Sell	18,582	$37.69	$700,355.58	29,910
9/21/2015	Samir Chandrakant Patel	President	Sell	27,215	$46.34	$1,261,143.10	259,292
8/31/2015	David R. Guyer	CEO	Sell	18,582	$44.88	$833,960.16	29,910
8/20/2015	Samir Chandrakant Patel	President	Sell	27,215	$48.75	$1,326,731.25	259,292
7/20/2015	Samir Chandrakant Patel	President	Sell	27,215	$67.87	$1,847,082.05
7/17/2015	Glenn Sblendorio	Director	Sell	3,000	$67.33	$201,990.00
7/1/2015	Barbara A Wood	SVP	Sell	2,000	$51.94	$103,880.00
6/29/2015	David R Guyer	CEO	Sell	18,582	$51.05	$948,611.10
6/18/2015	Samir Chandrakant Patel	President	Sell	12,000	$49.78	$597,360.00
5/28/2015	David R Guyer	CEO	Sell	18,582	$48.62	$903,456.84
4/29/2015	David R Guyer	CEO	Sell	18,582	$48.45	$900,297.90
4/17/2015	Samir Chandrakant Patel	President	Sell	12,000	$50.47	$605,640.00
3/30/2015	Axel Bolte	Director	Buy	500	$48.27	$24,135.00
3/30/2015	David R Guyer	CEO	Sell	18,582	$48.26	$896,767.32
3/2/2015	Barbara A Wood	SVP	Sell	2,000	$53.26	$106,520.00
3/2/2015	David R Guyer	CEO	Sell	18,582	$53.22	$988,934.04
1/2/2015	David R Guyer	CEO	Sell	15,034	$45.34	$681,641.56
11/13/2014	A/S Novo	Major Shareholder	Sell	995,000	$40.20	$39,999,000.00
11/3/2014	David R Guyer	CEO	Sell	15,034	$39.71	$597,000.14
10/2/2014	David R Guyer	CEO	Sell	2,807	$38.52	$108,125.64
10/2/2014	Samir Chandrakant Patel	President	Sell	1,965	$38.04	$74,748.60
10/1/2014	David R Guyer	CEO	Sell	12,227	$37.30	$456,067.10
10/1/2014	Samir Chandrakant Patel	President	Sell	17,676	$37.28	$658,961.28
9/4/2014	David R Guyer	CEO	Sell	1,107	$38.58	$42,708.06
8/1/2014	Bruce Peacock	CFO	Sell	6,191	$37.78	$233,895.98
8/1/2014	David R Guyer	CEO	Sell	13,136	$37.85	$497,197.60
8/1/2014	Samir Chandrakant Patel	President	Sell	18,986	$37.80	$717,670.80
7/1/2014	Bruce Peacock	CFO	Sell	7,739	$41.07	$317,840.73
7/1/2014	David R Guyer	CEO	Sell	15,034	$41.08	$617,596.72
7/1/2014	Samir Chandrakant Patel	President	Sell	18,986	$41.08	$779,944.88
6/16/2014	Nicholas Galakatos	Director	Sell	144,976	$44.17	$6,403,589.92
6/11/2014	Lifesciences Ii L.P. Clarus	Major Shareholder	Sell	211,680	$45.42	$9,614,505.60
6/4/2014	Svlsf Iv, Llc	Major Shareholder	Sell	1,966,935	$42.54	$83,673,414.90
6/3/2014	Bruce Peacock	CFO	Sell	13,931	$40.12	$558,911.72
6/3/2014	Svlsf Iv, Llc	Major Shareholder	Sell	1,865,619	$40.65	$75,837,412.35
6/2/2014	David R Guyer	CEO	Sell	25,417	$39.92	$1,014,646.64
6/2/2014	Samir Chandrakant Patel	President	Sell	27,873	$39.91	$1,112,411.43
5/30/2014	Svlsf Iv, Llc	Major Shareholder	Sell	931,869	$40.99	$38,197,310.31
5/28/2014	Svlsf Iv, Llc	Major Shareholder	Sell	980,127	$40.19	$39,391,304.13
5/23/2014	Svlsf Iv, Llc	Major Shareholder	Sell	330,450	$38.10	$12,590,145.00
5/13/2014	Hbm Healthcare Investments (Ca	major shareholder	Sell	500,000	$29.75	$14,875,000.00	3,139,902
5/1/2014	Bruce Peacock	CFO	Sell	4,643	$32.43	$150,572.49
5/1/2014	David Guyer	CEO	Sell	10,665	$33.71	$359,517.15	11,891
5/1/2014	Samir Chandrakant Patel	President	Sell	14,319	$32.45	$464,651.55	104,472
3/24/2014	Bruce Peacock	CFO	Sell	6,137	$34.77	$213,383.49
3/24/2014	David Guyer	CEO	Sell	12,027	$34.53	$415,292.31	34,583
3/24/2014	Samir Chandrakant Patel	President	Sell	16,876	$34.54	$582,897.04	135,667
2/18/2014	Svlsf Iv, Llc	major shareholder	Sell	2,111,364	$29.61	$62,517,488.04	140,228
9/30/2013	A/S Novo	Insider	Buy	455,000	$22.00	$10,010,000.00
9/30/2013	Hbm Healthcare Investments (Ca	Major Shareholder	Buy	228,000	$22.00	$5,016,000.00

(Data available from 1/1/2013 forward)

Ophthotech (NASDAQ OPHT) News Headlines

Source:

Date	Headline
	Ophthotech (OPHT) Upgraded to "Buy" at ValuEngine www.americanbankingnews.com - April 8 at 11:17 AM
	Ophthotech (OPHT) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - April 5 at 5:40 PM
	Insider Selling: Ophthotech (OPHT) Insider Sells 6,838 Shares of Stock www.americanbankingnews.com - April 3 at 11:04 PM
	Ophthotech (OPHT) Rating Lowered to D+ at TheStreet www.americanbankingnews.com - March 24 at 12:11 PM
	Regeneron Eylea Hits 24-Week Primary Endpoint in Study - Nasdaq ... - Nasdaq www.nasdaq.com - March 21 at 8:40 AM
	Regeneron Eylea Hits 24-Week Primary Endpoint in Study finance.yahoo.com - March 21 at 8:39 AM
	Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In ... - Benzinga www.benzinga.com - March 20 at 8:19 AM
	Ophthotech (OPHT) Rating Lowered to Underweight at JPMorgan Chase & Co. www.americanbankingnews.com - March 19 at 10:59 AM
	Ophthotech Corp (OPHT) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - March 11 at 6:18 PM
	Ophthotech (OPHT) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 7 at 12:49 PM
	Stonepine Capital Management LLC Lowers Holdings in Ophthotech Corp (OPHT) www.americanbankingnews.com - March 6 at 2:56 PM
	Tamarack Advisers LP Has $2.34 Million Position in Ophthotech Corp (OPHT) www.americanbankingnews.com - March 6 at 10:30 AM
	Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference - Business Wire (press release) www.businesswire.com - March 6 at 8:09 AM
	Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference finance.yahoo.com - March 6 at 8:09 AM
	Ophthotech Corp (OPHT) Position Reduced by Bogle Investment Management L P DE www.americanbankingnews.com - March 6 at 5:04 AM
	Ophthotech (OPHT) Downgraded by ValuEngine to Hold www.americanbankingnews.com - March 4 at 12:48 PM
	Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results - Business Wire (press release) www.businesswire.com - March 1 at 8:09 AM
	Ophthotech's (OPHT) CEO Glenn Sblendorio on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 1 at 8:09 AM
	Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus - Nasdaq www.nasdaq.com - March 1 at 8:09 AM
	Blog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal Diseases finance.yahoo.com - March 1 at 8:09 AM
	Ophthotech (OPHT) Given New $4.00 Price Target at Chardan Capital www.americanbankingnews.com - February 28 at 4:34 PM
	Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus www.zacks.com - February 28 at 8:11 AM
	Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results finance.yahoo.com - February 27 at 5:59 PM
	Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy finance.yahoo.com - February 27 at 5:59 PM
	Ophthotech (OPHT) Announces Earnings Results, Beats Estimates By $0.29 EPS www.americanbankingnews.com - February 27 at 9:12 AM
	Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy - Business Wire (press release) www.businesswire.com - February 27 at 8:12 AM
	Ophthotech (OPHT) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - February 22 at 1:16 PM
	Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - Business Wire (press release) www.businesswire.com - February 21 at 8:15 AM
	Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018 finance.yahoo.com - February 21 at 8:15 AM
	Ophthotech Corp (OPHT) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - February 14 at 5:34 PM
	Ophthotech Corp (OPHT) Receives Average Recommendation of "Buy" from Brokerages www.americanbankingnews.com - January 20 at 5:38 PM
	Ophthotech Begins Phase II Zimura Study in Stargardt Disease www.zacks.com - January 17 at 10:10 AM
	Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of ... www.businesswire.com - January 16 at 4:38 PM
	Ophthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for Treatment of STGD1 www.streetinsider.com - January 16 at 4:38 PM
	Ophthotech Corp (OPHT) Enrolls First Patient in Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for ... - StreetInsider.com www.streetinsider.com - January 16 at 10:14 AM
	Ophthotech Corp (OPHT) Elects Jane Pritchett Henderson to Board - StreetInsider.com www.streetinsider.com - January 16 at 10:14 AM
	Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of Directors finance.yahoo.com - January 16 at 10:14 AM
	Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1) finance.yahoo.com - January 16 at 10:14 AM
	Technical Perspectives on Biotech Stocks -- Ophthotech, Trevena, PTC Therapeutics, and Halozyme Therapeutics - PR Newswire (press release) www.prnewswire.com - January 10 at 10:21 AM
	Ophthotech (OPHT) & Flex Pharma (FLKS) Head-To-Head Analysis www.americanbankingnews.com - January 9 at 3:42 PM
	Ophthotech Corp (OPHT) Insider Sells $12,039.66 in Stock www.americanbankingnews.com - January 5 at 6:50 PM
	David R. Guyer Sells 16,520 Shares of Ophthotech Corp (OPHT) Stock www.americanbankingnews.com - January 3 at 7:54 PM
	Glenn Sblendorio Sells 8,089 Shares of Ophthotech Corp (OPHT) Stock www.americanbankingnews.com - January 3 at 7:54 PM
	Insider Selling: Ophthotech Corp (OPHT) SVP Sells 5,289 Shares of Stock www.americanbankingnews.com - January 3 at 7:54 PM
	Ophthotech Corporation to Present at the 36th Annual J.P. Morgan ... - Business Wire (press release) www.businesswire.com - January 2 at 10:33 PM
	Ophthotech Corporation to Present at the 36th Annual J.P. Morgan Healthcare Conference finance.yahoo.com - January 2 at 10:07 AM
	ValuEngine Downgrades Ophthotech (OPHT) to Hold www.americanbankingnews.com - January 1 at 2:20 PM
	Comparing Ophthotech (OPHT) and Its Rivals www.americanbankingnews.com - December 28 at 3:21 AM
	Ophthotech Corp (OPHT) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - December 26 at 6:46 PM
	Critical Review: Ophthotech (OPHT) versus The Competition www.americanbankingnews.com - December 23 at 3:07 AM

Ophthotech (NASDAQ:OPHT) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Ophthotech (NASDAQ:OPHT) Income Statement, Balance Sheet and Cash Flow Statement

Ophthotech (NASDAQ OPHT) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff